Abstract:e16040 Background: The combined modality therapy including neoadjuvant chemoradiotherapy has been selected as the standard care for locally advanced Esophageal squamous cell carcinoma (ESCC). However, the conclusive evidences to support the effectiveness of neoadjuvant immunotherapy for ESCC are rarely discussed. This study aims to investigate the molecular features of cell-free DNA (cfDNA) and the impact of their dynamic changes on the response to neoadjuvant immunotherapy in locally advanced ESCC patients. Methods: Twenty-four eligible locally advanced ESCC patients with received neoadjuvant immunotherapy were enrolled in this study. 7 patients achieved pathological complete regression (pCR) and the other 17 patients had non-pCR. The baseline, second and third blood samples (before neoadjuvant immunotherapy, at one month and two months after neoadjuvant immunotherapy, respectively) were collected from Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Both cfDNA fragments and genomic DNA were extracted for enrichment of a customized panel covering exon regions of 599 genes. The dynamic analysis of gene alterations, which allows the monitoring of the response to neoadjuvant immunotherapy in locally advanced ESCC patients, were conducted based on multiple blood sampling strategy. Results: The most frequently mutated genes among all cases were TP53, KMT2D, CREBBP and KMT2B. MSI scores of both second and third blood samples were remarkablely higher than those in baseline blood samples (p = 0.002, 0.04). On the contrary, the TMB values and mean variant allele frequency (VAF) of second and third blood samples were significantly decreased compared with the baseline blood (TMB, p = 0.04, 0.03; mean VAF, p = 0.01, 0.02). Moreover, a decreasing trend of mean VAF was observed at the time-series blood samples from ESCC patients with pCR, while the mean VAF of ESCC patients with non-pCR declined in the blood samples from the second time point then increased in the blood samples from the thrid time point. Conclusions: The detection of dynamic changes of mean VAF could distinguish the pCR and non-pCR ESCC patients with neoadjuvant immunotherapy. These findings warrant further expanded prospective cohorts to validate.

[Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous  Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma].

Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance

[Progress of Individualized Chemotherapy Guided by Chemosensitivity Test].

Evaluation of the in Vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer Using the ATP-TCA.

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Application of a Microfluidic Chip-Based 3D Co-Culture to Test Drug Sensitivity for Individualized Treatment of Lung Cancer.

Laboratory Techniques for Predicting Chemosensitivity in Malignant Glioma and Their Clinical Application

Study on Chemosensitivity of Peripheral Blood Lymphocytes and Tumor Cells of Tumor Patients in Vitro

In Vitro Chemosensitivity Testing of Primary and Recurrent Breast Carcinomas and Its Clinical Significance

Non-Invasive Detection of Biomechanical and Biochemical Responses of Human Lung Cells to Short Time Chemotherapy Exposure Using Afm and Confocal Raman Spectroscopy

Clinical adjuvant chemotherapy base on chemosensitivity in nude mouse subrenal capsule assay for non-small cell lung cancer]

A Metabonomic Approach To Chemosensitivity Prediction Of Cisplatin Plus 5-Fluorouracil In A Human Xenograft Model Of Gastric Cancer

Clinical Evaluation of Serum Tumor Markers in Patients with Advanced-Stage Non-Small Cell Lung Cancer Treated with Palliative Chemotherapy in China

Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.

Study on the chemosensitivity test with TECIA in vitro for the choice of individualized chemotherapy of lung cancer

Chemosensitivity testing as an aid to anti-cancer drug and regimen development

Chemical and Biological Evidence of the Efficacy of Shengxian Decoction for Treating Human Lung Adenocarcinoma

Alterations of Serum Inflammatory Biomarkers in the Healthy and Lung Cancer Patients Before and Post Chemotherapy

Towards Personalized Medicine: Chemosensitivity Assays of Patient Lung Cancer Cell Spheroids in A Perfused Microfluidic Platform

Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions

Characterization of ascites‐derived tumor cells from an endometrial cancer patient

[Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma].